Login to Your Account



Ra, Merck Partner to Develop Peptide Drugs in $200M Deal

By Catherine Shaffer
Staff Writer

Wednesday, April 3, 2013
A new collaboration between Ra Pharmaceuticals Inc. and Merck & Co. Inc. will focus on harnessing the therapeutic power of peptide drugs through a platform technology that offers candidates pre-designed for cell permeability and oral bioavailability.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription